toxins
Article
Coagulotoxicity of Bothrops (Lancehead Pit-Vipers)
Venoms from Brazil: Differential Biochemistry and
Antivenom Efficacy Resulting from Prey-Driven
Venom Variation
Leijiane F. Sousa 1,2 , Christina N. Zdenek 2 , James S. Dobson 2 , Bianca op den Brouw 2 ,
Francisco C. P. Coimbra 2 , Amber Gillett 3 , Tiago H. M. Del-Rei 1 , Hipócrates de M. Chalkidis 4 ,
Sávio Sant’Anna 5 , Marisa M. Teixeira-da-Rocha 5 , Kathleen Grego 5 ,
Silvia R. Travaglia Cardoso 6 , Ana M. Moura da Silva 1 and Bryan G. Fry 2, *
1
2
3
4
5
6
*
Laboratório de Imunopatologia, Instituto Butantan, São Paulo 05503-900, Brazil;
leijiane.sousa@butantan.gov.br (L.F.S.); tiago.moretto@butantan.gov.br (T.H.M.D.-R.);
ana.moura@butantan.gov.br (A.M.M.d.S.)
Venom Evolution Lab, School of Biological Sciences, University of Queensland,
St. Lucia, QLD 4072, Australia; christinazdenek@gmail.com (C.N.Z.); j.dobson@uq.edu.au (J.S.D.);
b.opdenbrouw@uq.edu.au (B.o.d.B.); francisco.cp.coimbra@gmail.com (F.C.P.C.)
Fauna Vet Wildlife Consultancy, Glass House Mountains, QLD 4518, Australia; drambergillett@hotmail.com
Laboratório de Pesquisas Zoológicas, Unama Centro Universitário da Amazônia, Pará 68035-110, Brazil;
hchalkidis@gmail.com
Laboratório de Herpetologia, Instituto Butantan, São Paulo 05503-900, Brazil;
savio.santanna@butantan.gov.br (S.S.); marisa.rocha@butantan.gov.br (M.M.T.-d.-R.);
kathleen.grego@butantan.gov.br (K.G.)
Museu Biológico, Insituto Butantan, São Paulo 05503-900, Brazil; silvia.cardoso@butantan.gov.br
Correspondence: bgfry@uq.edu.au
Received: 18 September 2018; Accepted: 8 October 2018; Published: 11 October 2018
Abstract: Lancehead pit-vipers (Bothrops genus) are an extremely diverse and medically important
group responsible for the greatest number of snakebite envenomations and deaths in South America.
Bothrops atrox (common lancehead), responsible for majority of snakebites and related deaths within
the Brazilian Amazon, is a highly adaptable and widely distributed species, whose venom variability
has been related to several factors, including geographical distribution and habitat type. This study
examined venoms from four B. atrox populations (Belterra and Santarém, PA; Pres. Figueiredo, AM
and São Bento, MA), and two additional Bothrops species (B. jararaca and B. neuwiedi) from Southeastern
region for their coagulotoxic effects upon different plasmas (human, amphibian, and avian). The results
revealed inter– and intraspecific variations in coagulotoxicity, including distinct activities between the
three plasmas, with variations in the latter two linked to ecological niche occupied by the snakes.
Also examined were the correlated biochemical mechanisms of venom action. Significant variation in the
relative reliance upon the cofactors calcium and phospholipid were revealed, and the relative dependency
did not significantly correlate with potency. Relative levels of Factor X or prothrombin activating toxins
correlated with prey type and prey escape potential. The antivenom was shown to perform better in
neutralising prothrombin activation activity than neutralising Factor X activation activity. Thus, the data
reveal new information regarding the evolutionary selection pressures shaping snake venom evolution,
while also having significant implications for the treatment of the envenomed patient. These results are,
therefore, an intersection between evolutionary biology and clinical medicine.
Keywords: venoms; coagulotoxicity; antivenom; variations; adaptive pressures; venom induced
consumptive coagulopathy
Toxins 2018, 10, 411; doi:10.3390/toxins10100411
www.mdpi.com/journal/toxins
Toxins 2018, 10, 411
2 of 23
Key Contribution: Substantial variations in the procoagulant activity of the Bothrops genus—the
most medically important snake group in South America—were documented; including intra-specific
venom variations across B. atrox populations. This study provides important insights the role of prey
type in shaping venom evolution and about relative neutralisation by antivenoms.
1. Introduction
Snakebite is a global crisis due to its neglect relative to other tropical diseases [1]. Snake venoms
can attack a myriad of physiological systems, affecting blood coagulation or blood pressure, causing cell
death, selectively damaging muscle cells, or interfering with nerve transmission either by preventing
nerve signals or preventing nerves from being turned off [2]. However, due to inherent difficulties in
working with blood enzyme cascades, research into coagulotoxicity has lagged behind other intensively
studied areas such as neurotoxicity. In addition, of the coagulotoxin studies that have been undertaken,
only some [3–9] have included in the experimental design the cofactors calcium and phospholipid,
which are necessary to replicate physiological conditions in in vitro assays. Other studies have included
only calcium [10–15], or neither cofactor [16–18], leading to deficiencies in replicating physiological
conditions and interfering with accurate interpretation of the effects upon coagulation.
The Bothrops genus (lancehead pit-vipers) is an extremely diverse [19] and medically significant
snake group, responsible for the majority of envenomations and deaths related to snakebites in
South America [20,21]. The main clinical effects of the envenoming by Bothrops snakes includes local
tissue damage (edema, haemorrhage, and myonecrosis), and systemic effects resulting mainly in blood
coagulation disorders [22]. The main protein families involved in systemic coagulopathic effects are snake
venom metalloproteinases (SVMPs), snake venom serine proteinase (SVSPs), phospholipases (PLA2 s) and
C-type Lectins (CTLs). These toxins are able to act on components of the coagulation cascade, promote
haemorrhage, and interfere with the formation of the haemostatic plug and platelet aggregation [23–29].
Within the Bothrops genus, Bothrops atrox (common lancehead pit-viper) causes more human
fatalities than any other South American snake [20]. B. atrox is a highly adaptable species which is
widely distributed in a large part of the tropical plains of South America [19] and are also prevalent
throughout the Brazilian Amazon. This species is responsible for the most snakebites in the Amazon
region [30], and the variability in their venoms has been reported according to ontogeny [31,32],
between populations [33–35], and within populations [36,37], even extending to the habitat type [38].
Venom variability within B. atrox snakes has been related to diverse factors including geographical
distribution [33–35] and habitat variation [38], which likely reflect variances in prey type and prey
escape potential. Venom variability of this species can produce functional diversity able to affect
antivenom efficacy, as demonstrated previously by in vitro assays [38,39].
Venom variability associated with functional diversity is particularly critical regarding reactivity
with antivenoms, as recently reported in a study involving venoms from B. atrox snakes captured
in distinct habitats of Western Pará, Brazilian Amazon [38]. This study reported remarkable
functional differences in the venom of a B. atrox population (from a floodplain habitat), whose high
procoagulant activity was not efficiently neutralised by antivenoms. Antivenoms in general are made
using an immunising mixture which includes only a limited range of venoms obtained from few
species [40]. One complicating matter is that venom composition may vary considerably among
different species and, as related above [36,37], between populations within a single species [41].
Therefore, antivenom efficacy may vary considerably due to inter-species and intra-specific variation
in venom composition [8].
In Brazil, Bothrops antivenom is produced from plasma of horses immunised with a venom mixture
of the following species: Bothrops jararaca (50%), Bothrops neuwiedi (12.5%), Bothrops alternatus (12.5%),
Bothrops moojeni (12.5%), and Bothrops jararacussu (12.5%); however, despite its great medical
importance, B. atrox venom is not included in this immunising mixture.
Toxins 2018, 10, 411
3 of 23
Bothrops species are notable amongst pit-vipers in having the ability to profoundly affect
blood chemistry through the procoagulant action of Factor X activation and prothrombin
activation [10,39,42–49]. In 1979, Nahas and colleagues undertook a comparative study of 26 Bothrops
species and reported that prothrombin or Factor X activation functions were present in all Bothrops
species, in addition to the ability to directly clot fibrinogen, but with high degrees of variability
within the genus [50]. More recently, studies about intra and inter-specific variations in Bothrops
venoms reported differences in procoagulant components between species and within populations of
a particular species [39].
It has been demonstrated that SVMPs, particularly of P-III class, are the most abundant within
the Bothrops genus [51] and also the most antigenic and immunoreactive components in the Bothrops
venoms, including some B. atrox populations from the Brazilian Amazon [33,51]. Consequently, many
SVMPs have already been isolated from Bothrops venoms, several of which were able to activate
coagulation factors, particularly Factor X and prothrombin [47–49,52–55]. Factor V, Factor VII, Factor X,
and prothrombin activators have been found in B. atrox venoms which were already isolated and
characterised, at least partially [42–44]. In B. neuwiedi venom, Factor X and prothrombin activators
have been isolated and characterised [49], and from B. jararaca venom a prothrombin activator has
also been isolated and characterised [54]. Other characterised toxin types include serine proteases
which act in a pseudo-procoagulant manner by cleaving fibrinogen to form transient, weak fibrin clots,
and also serine proteases which generate endogenous thrombin [56–58].
Despite the aforementioned studies on coagulotoxins within Bothrops venoms, little has been
investigated regarding evolutionary variations in the basic underlying biochemistries, such as
relative dependence on the calcium or phospholipid cofactors, and how this influences function.
In addition, a more systematic investigation has not been undertaken to evaluate the Bothrops
antivenom efficacy against procoagulant mechanisms of Factor X activation and prothrombin activation.
Another important under-investigated issue which concerns the ecology of snakes is the relative venom
potency of different Bothrops species and populations on taxon-specific plasma. Most studies to date
have tested venoms against only one type of plasma, usually from humans or rodents [45,51]. The sole
study in this regard showed that purified SVMPs, isolated from B. neuwiedi venom, differentially
affected human, rat, and chicken plasmas [49].
Therefore, in order to fill the aforementioned knowledge gaps, this study examined venoms of
four populations of B. atrox snakes, captured from different habitat types within the Brazilian Amazon,
in addition to two other Bothrops species, B. jararaca and B. neuwiedi, whose venoms are used for the
production of the Instituto Butantan Bothrops antivenom. These venoms were submitted to a battery of
analyses to provide a comprehensive examination of the venom effects: (i) relative coagulotoxicity;
(ii) relative dependence of venoms on cofactors (calcium and phospholipid); (iii) relative efficacy of
the Bothrops antivenoms against Bothrops venoms; and (iv) taxon-specific effects on amphibian, avian,
and human plasma. The results obtained in this study advance our understanding of evolutionary
selection pressures, serum therapy for human envenomations, and the fundamental biochemistry
underpinning venom variation.
2. Results
2.1. Coagulation Analyses Using a Stago STA-R Max Coagulation Analysis Robot
2.1.1. Plasma Clotting Activity
The venoms showed appreciable variation in their clotting times at the 20 µg/mL concentration,
with the rank order from most to least potent, in seconds until clot formed, as follows: B. atrox
(Santarém, PA) 11.1 ± 0.05; B. neuwiedi (São Paulo, SP) 13.5 ± 0.7; B. atrox (Belterra, PA) 20.3 ± 0.2;
B. jararaca (São Paulo, SP) 21.2 ± 0.7; B. atrox (Pres. Figueiredo, AM) 25.5 ± 0.3; and B. atrox
(São Bento MA) 30.1 ± 6.1. In order to further elucidate greater resolution of the relative procoagulant
activity of the venoms, 8-point dilution curves were conducted (20, 10, 4, 1.667, 0.667, 0.25, 0.125,
Toxins 2018, 10, 411
4 of 23
and 0.05 µg/mL). Significant variation was again evident in the procoagulant toxicity, with the
Santarém population again considerably more toxic than the other B. atrox populations, in addition to
B. jararaca, and B. neuwiedi, as demonstrated by having a much smaller area under the curve (Figure 1).
The rank order (from most to least potent) for the dilution curves was the same as the rank order for the
20 µg/mL concentrations: B. atrox (Santarém, PA) 272.4 ± 0.8; B. neuwiedi (São Paulo, SP) 331.8 ± 7.4;
B. atrox (Belterra, PA) 527.5 ± 1.2; B. jararaca (São Paulo, SP) 553.2 ± 6.3; B. atrox (Pres. Figueiredo,
AM) 635.2 ± 3.4; and B. atrox (São Bento, MA) 794.8 ± 31.7. The maximum clotting time at the highest
venom concentration and area under the dilution curves had a correlation of 0.997.
Figure 1. Variation in clotting speed, antivenom efficacy, and venom biochemistry measured on a Stago
STA-R Max coagulation analyser. 8-point dilutions are shown in curve and logarithmic presentations.
Venom is in red line, venom + antivenom in blue line. Relative procoagulant potency is visualised by
calculating 1/AUC, with AUC = area under the curve. Antivenom efficacy results are shift in AUC;
if no shift occurred, this would have a value of 0. Therefore, larger numbers are indicative of higher
relative antivenom efficacy.
Toxins 2018, 10, 411
5 of 23
Cofactor dependency studies: larger numbers indicate greater dependency, if there was no change
with or without a cofactor this would have a value of 0. Data points are n = 3 means and standard
deviations. Note for many data points in the curves the error bars are smaller than the line icons.
Antivenom efficacy (calculated by dividing the area under the curve for the antivenom dilution
series by the area under the curve for the dilution series without antivenom) was also variable (Figure 1).
The antivenom efficacy (presented as an x-fold shift in the area under the curve, whereby no shift
would have a value of 0) rank order (from best to poorest neutralised) was: B. atrox (São Bento, MA)
12.5 ± 0.1; B. atrox (Belterra, PA) 5.8 ± 0.1; B. jararaca (São Paulo, SP) 5.5 ± 0.5; B. atrox (Pres. Figueiredo,
AM) 5.4 ± 0.2; B. neuwiedi (São Paulo, SP) 2.9 ± 0.1; and B. atrox (Santarém PA) 2.1 ± 0.1. There was
an inverse correlation between potency and antivenom efficacy (−0.917), whereby the most potent
venoms were the least neutralised.
The venoms also differed in the basic biochemistry underpinning the procoagulant activity
(Figure 1). The calcium dependency (calculated as dividing the 20 µg/mL clotting time (with both
cofactors in the assay) by the 20 µg/mL clotting time with only phospholipid in the assay and
then subtracting 1, such that a value of zero would indicate no dependency) rank order (from most
dependent to least dependent) was: B. atrox (Pres. Figueiredo, AM) 4.4 ± 0.1; B. neuwiedi (São Paulo, SP)
3.0 ± 0.1; B. jararaca (São Paulo, SP) 2.9 ± 0.1; B. atrox (São Bento, MA) 1.5 ± 0.1; B. atrox (Belterra, PA)
1.04 ± 0.1; B. atrox (Santarém, PA) 0.8 ± 0.1. The phospholipid dependency (calculated as dividing the
20 µg/mL clotting time (with both cofactors in the assay) by the 20 µg/mL clotting time with only
calcium in the assay and then subtracting 1, such that a value of zero would indicate no dependency)
rank order was: B. atrox (Pres. Figueiredo, AM) 0.6 ± 0.001; B. neuwiedi (São Paulo, SP) 0.6 ± 0.001;
B. jararaca (São Paulo, SP) 0.5 ± 0.05; B. atrox (São Bento, MA) 0.2 ± 0.05; and B. atrox (Belterra, PA)
0.1 ± 0.001 = B. atrox (Santarém PA) 0.1 ± 0.001.
2.1.2. Factor X and Prothrombin Activation Activity
In order to ascertain relative activation of the zymogens Factor X and prothrombin, additional
tests were undertaken, including determining the relative efficacy of antivenom upon each activity
for each venom. Factor X activation activity was significantly correlated with procoagulant activity
(0.889) and prothrombin activation activity was also significantly correlated with procoagulant activity
(0.742), and they were strongly correlated with each other (0.824). Significant variation between
venoms was evident in the activation of each zymogen (Figure 2), with the Santarém population
considerably more effective than the other B. atrox populations in activating both Factor X and
also prothrombin. The Factor X activation rank order (from most to least potent) was: B. atrox
(Santarém, PA) 1.8 ± 0.09; B. neuwiedi (São Paulo, SP) 1.3 ± 0.05; B. atrox (Pres. Figueiredo, AM)
0.41 ± 0.07; B. atrox (Belterra, PA) 0.43 ± 0.01; B. jararaca (São Paulo SP) 0.27 ± 0.01; = B. atrox
(São Bento, MA) 0.27 ± 0.01. The prothrombin activation rank order (from most to least potent) was:
B. atrox (Santarém, PA) 1.45 ± 0.03; B. jararaca (São Paulo, SP) 0.44 ± 0.02; B. neuwiedi (São Paulo, SP)
0.38 ± 0.03; B. atrox (Pres. Figueiredo, AM); 0.15 ± 0.01; = B. atrox (Belterra, PA) 0.15 ± 0.01; B. atrox
(São Bento, MA) 0.11 ± 0.01. B. atrox (Santarém PA) much stronger than all other venoms in
both activities.
The antivenom was able to neutralise both activities but was much more effective in neutralising
the prothrombin activation activity than the Factor X activation activity (Figure 2). The antivenom was
particularly less effective in neutralising the Factor X activation activity of both B. atrox (Santarém, PA)
and B. neuwiedi relative to the neutralisation of the prothrombin activation by the same species.
These two venoms, B. atrox (Santarém) and B. neuwiedi, were also the most potently procoagulant,
and the least neutralised by antivenom in the plasma tests. There was, thus, an inverse relationship
between antivenom neutralisation of the plasma and the relative contribution of Factor X activation
activity contribution to procoagulation, whereby the venoms with the highest degree of Factor X
Toxins 2018, 10, 411
6 of 23
activation were the least neutralised. Prothrombin activation, however, was neutralised well for
all species.
Figure 2. Variation in the ability to activate the clotting zymogens Factor X and prothrombin, measured
on a Stago STA-R Max coagulation analyser. Activation studies: larger numbers indicate greater activity.
Antivenom assays: larger numbers indicate greater antivenom efficacy. Data points are n = 3 means
and standard deviations.
2.2. Thromboelastography Analyses Using Haemonetics TEG5000s
Thromboelastographic assays were undertaken using human, chicken and toad plasmas,
to characterise the main clot parameters in order to investigate possible selectivity of venom for
a specific type of plasma, in addition to tests on purified human fibrinogen.
2.2.1. Thromboelastography Tests Using Plasma
All the venoms showed the ability to rapidly clot human plasma to form strong, stable clots
(Figure 4). Testing on avian (Figure 5) and amphibian (Figure 6) plasmas, however, revealed
a differential activity. While the avian clotting patterns was congruent with that upon human plasma,
the amphibian plasma was discordant in this regard. This lack of congruence was largely due to
the inactivity of B. atrox (São Bento, MA) on amphibian plasma. However, unlike the tests upon
human and amphibian plasmas, none of the venoms were able to form clots in the avian plasma of the
same strength (MA) as the controls. Further, despite being the fastest venom (SP values in Figure 5),
the B. atrox (Santarém, PA) venom formed significantly weaker clots in the avian plasma (p = 0.02
for B. neuwiedi, the closest other venom) than the other venoms in that same plasma (MA values in
Figure 5). Also notable in the TEG analyses was that, unlike the avian and human plasmas, the toad
plasma did not spontaneously form a clot after being recalcified.
Toxins 2018, 10, 411
7 of 23
2.2.2. Thromboelastography Tests Using Fibrinogen
In order to ascertain the retention of the basal coagulotoxic action of fibrinogenolysis, additional
thromboelastography analyses were under taken using human fibrinogen in place of plasma.
All venoms showed the ability to rapidly form weak, pseudo-procoagulant clots when tested directly
on fibrinogen, with the exception of B. atrox (Pres. Figueiredo AM). This venom was notably weaker
and slower in this activity than the other venoms, with the R and MA not detectable, as they were
below the machine measurement threshhold (Figure 3).
2.3. Fibrinogen Gel Analyses
Next, in order to quantify fibrinogen chain cleavage specificity and relative rate of action,
additional fibrinogen assays were undertaken whereby venom was incubated with fibrinogen for
varying periods of time and then visualised using 1D SDS-PAGE gels (Figure 7), followed by
quantification of band densities (Figure 8). All venoms were faster to act—and more potent—upon the
Aalpha fibrinogen chain than the Bbeta chain and with greater variability in action seen for the Bbeta
chain relative to the highly conserved action on the Aalpha chain.
Figure 3. Variations in the ability of venoms to clot human fibrinogen, measured on Haemonetics
TEG5000 thromboelastography analysers for 30 min. For visualisation purposes, the venom
experimental traces are overlaid with the thrombin control. All traces are n = 3. Values are n = 3
means and standard deviation. SP = Split Point- the time at which clot formation starts; R = time to
reach 2 mm amplitude; MA = maximum amplitude.
Toxins 2018, 10, 411
8 of 23
Figure 4. Variations in the ability of venoms to clot human plasma, measured on Haemonetics TEG5000
Thromboelastography analysers for 30 min. For visualisation purposes, the Factor Xa control, thrombin
control, and venom experimental traces are overlaid with the spontaneous clotting negative control.
All traces are n = 3. Values are n = 3 means and standard deviation. SP = split point—the time at which
clot formation starts; R = time to reach 2 mm amplitude; MA = maximum amplitude.
Figure 5. Variations in the ability of venoms to clot avian plasma, measured on Haemonetics TEG5000
Thromboelastography analysers for 30 min. For visualisation purposes, the Factor Xa control, thrombin
control, and venom experimental traces are overlaid with the spontaneous clotting negative control.
All traces are n = 3. Values are n = 3 means and standard deviation. SP = split point—the time at which
clot formation starts; R = time to reach 2 mm amplitude; MA = maximum amplitude.
Toxins 2018, 10, 411
9 of 23
Figure 6. Variations in the ability of venoms to clot amphibian plasma, measured on Haemonetics
TEG5000 Thromboelastography analysers for 30 min. For visualisation purposes, the venom
experimental traces are overlaid with the Factor Xa control. All traces are n = 3. Values are n = 3 means
and standard deviation. SP = Split Point- the time at which clot formation starts; R = time to reach
2 mm amplitude; MA = maximum amplitude. N.D. = not detectable.
Toxins 2018, 10, 411
10 of 23
Figure 7. 1D SDS-PAGE visualisation of fibrinogenolytic effects. F0 = time 0 min fibrinogen control;
F60 = time 60 min fibrinogen control; 1, 5, 20, and 60 = experimental time periods. Each condition was
run in triplicate. Representative gels are shown.
Toxins 2018, 10, 411
11 of 23
Figure 8. Differential effect upon Aalpha and Bbeta fibrinogen chains. Data points are n = 3 means and
standard deviations.
3. Discussion
We investigated differences in the venom biochemistry influencing procoagulant action and
reactivity with Bothrops antivenom in B. atrox populations from different locations in the Brazilian
Toxins 2018, 10, 411
12 of 23
Amazon (Santarém and Belterra–PA, São Bento–MA, Pres. Figueiredo–AM) in addition two other
Bothrops species (B. jararaca and B. neuwiedi) of great medical importance in Brazil. This study
documented significant variation not only in procoagulant potency of the venoms between the
three species (B. atrox, B. jararaca, and B. neuwiedi), but also revealed previously undocumented
intraspecific variation between populations of B. atrox from the Brazilian Amazon (Figure 1).
Geographical variations in clotting and fibrinolytic activities of B. atrox venoms from Venezuela
have been reported [35], where significant differences in clotting speed were observed, but cofactor
dependency was not investigated, which prevents a comparison with our results. In addition, these
authors also did not evaluate antivenom efficacy against these activities.
All Bothrops species and populations in the present study shared the derived procoagulant activities
that makes this genus unique amongst American pit-vipers. These venoms generate endogenous
thrombin through the activation of Factor X and prothrombin (Figure 2), resulting in strong, stable
fibrin clots in the plasma. Thromboelastography comparison of derived procoagulant action on plasma
due to the Factor X and prothrombin activation functions (Figure 4), in comparison to the ancestral
pseudo-procoagulant action upon fibrinogen to directly form weak, unstable fibrin clots (Figures 7 and 8),
indicates that the derived action thrombin generating function is faster and stronger, and therefore would
be the driving force in prey subjugation. However, the fact that all Bothrops species and B. atrox populations
had both procoagulant and pseudo-procoagulant functions is consistent with the complex coagulopathic
effects produced in human envenomation by Bothrops snakes [22].
In human bite victims, the dilution of the venom into such a large blood volume would result in
venom-induced consumption coagulopathy due to the procoagulant toxin generation of endogenous
thrombin, which consumes the clotting factors, resulting in a disappearance of fibrinogen and a net
anticoagulant state [59]. In such a scenario, unlike prey items which rapidly succumb to the venom,
human victims would survive long enough for the pseudo-procoagulant actions to form weak, transient
clots with remaining fibrinogen, thereby potentiating the net anticoagulation effects. These weak
clots were demonstrated by our thromboelastographic analyses using human fibrinogen instead of
plasma for all venoms analysed in this study, with particularly weak clots formed by the B. atrox
venom from the Pres. Figueiredo population (Figure 3). In fibrinogen gel analyses, the venoms each
showed similar cleavage profiles for Aalpha chain, slightly variation upon the Bbeta, and no effects on
gamma chain. Pseudo-procoagulant activity on fibrinogen has been associated with thrombin-like
enzymes (SVSPs), while non-clotting fibrinogenolytic properties can be related to both thrombin-like
enzymes and fibrinogenolytic SVMPs [60]. Most SVMPs with fibrinogenolytic activity cleave Aalpha
and Bbeta chains with preference for the former [61].
Of particular concern in our study is that the ability of the antivenom to neutralise the
procoagulant activity of these medically important snakes varied substantially. This was especially
the case for the extremely potent B. atrox Santarém population, which was not only the most potent
but also the least neutralised (Figure 1). B. atrox venom from Santarém population was obtained
from snakes collected in a floodplain (várzea) habitat, and these findings corroborate previous results
reported by Sousa and colleagues showing a low neutralisation of the procoagulant activity of this
venom by Bothrops antivenom [38]. The B. neuwiedi venom was nearly as potent as the B. atrox Santarém
population and was similarly not well neutralised by the antivenom. In contrast, B. jararaca venom and
the B. atrox populations (Belterra-PA, Pres. Figueiredo-AM and São Bento-MA) were neutralised with
greater efficacy (Figure 1). These findings are surprising, considering that B. jararaca and B. neuwiedi
venoms are included in the immunising mixture used to prepare the antivenom. B. jararaca makes up
50% of the immunisation mixture, and was well neutralised. In contrast, B. neuwiedi represents 12.5%
of the immunising mixture, it was poorly neutralised. However, this does not seem to be a simple
quantitative matter, since the antivenom also showed a high efficacy against the venoms of three of the
four B. atrox populations, despite the venom of this species not being used in the immunising mixture.
The lowest relative efficacy of the antivenom against the procoagulant activity induced by venoms
of B. atrox from Santarém and B. neuwiedi correlates with a higher amount of Factor X activating toxins
Toxins 2018, 10, 411
13 of 23
in these two venoms (Figure 2). In contrast, the Bothrops antivenom was very efficient in preventing
prothrombin activation by all venoms. These results thus suggest that the antivenom performs better in
neutralising prothrombin activating toxins than Factor X activating toxins. The poor antivenom plasma
performance for B. atrox (Santarém) and B. neuwiedi thus appears to stem from poorly-neutralised
Factor X activation activity for these two species, while the prothrombin activation activity was well
neutralised for both species. In contrast, the other species did not display such significant variation
in neutralisation by antivenom for Factor X versus prothrombin activation activity. This suggests
the surface chemistry and geometry for the Factor X activating toxins in the B. atrox (Santarém) and
B. neuwiedi venoms differ from that of the other venom studied here, and that these variations influence
antivenom epitope-paratope interations.
Our results not only reveal that Bothrops venoms are extremely potently procoagulant, but that
there is significant variation in dependence of the venoms on the cofactors calcium and phospholipid,
with relative reliance not correlated with overall potency (Figure 1) or relative Factor X or prothrombin
activation activity (Figure 2). During plasma collection, calcium is deliberately stripped out of the
plasma through the use of citrate as a preservative in order to prevent spontaneous coagulation.
Therefore, the replenishment of calcium to the plasma is necessary to replicate physiological conditions.
In addition, various steps of the coagulation cascade involve enzyme cleavage of zymogens
(proenzymes) to generate thrombin, with most of these cleavage steps occurring on negatively charged
phospholipid membrane surfaces, with the requirement of calcium ions [3,62]. Activated platelets
are the major source of phospholipids in the blood, therefore laboratory tests using platelet poor
plasma are deficient in a source of phospholipid. While the venoms were still active, to a degree, in the
absence of one or both cofactors, the relative activity was reduced, and the decrease in activity
varied between venoms for both cofactors. Therefore, conducting tests in the presence of both
cofactors is essential to properly ascertain activity and therefore determine the real-world efficacy
of antivenoms. Previous work on crude venoms and purified fractions have in some cases conducted
assays with and without one or both cofactors [48,53,55,63], but did not present relative activities for
the cofactor presence or absence and, therefore, those prior studies cannot be directly compared to
our results. Other studies on Bothrops crude venoms or purified fractions did not include either cofactor,
which likely resulted in reportedly lower toxicities than noted here [18,42–44,54]. One study which
investigated calcium dependency for B. asper venoms from Mexico determined that those venoms
were not calcium-dependent [10].
One interesting aspect for a biological interpretation of the data is that most of the studies
related to procoagulant activity of Bothrops venoms have been performed with human plasma and
interpreted according to human envenomings. However, it has been accepted that procoagulant
activity is a fundamental feature of pit-viper venoms for the purpose of prey capture. In prey animals,
the rapid formation of endogenous thrombin by Bothrops venom could result in prey incapacitation
through stroke induction, with this function convergent with not only other vipers such a Echis [8],
but diverse snakes from other families such as Dispholidus and Thelotornis with the Colubridae [9],
Hoplocephalus, Notechis, Paroplocephalus, and Tropidechis within the Elapidae [5], and Atractaspis within
the Lamprophiidae [6]. In addition, snake venom variability has been correlated to differences in the
diet of snakes from different geographical regions [64].
In consideration of the importance of procoagulant effects of the venom to Bothrops snakes to
subjugate prey items, thromboelatographic analyses were undertaken to investigate the main clot
parameters in animal plasmas as models of amphibian (cane toad) and avian (chicken) potential prey
types in comparison to the effects on human plasma. This study revealed taxon-specific venom effects,
which could be consistent with the evolutionary history of the B. atrox populations regarding selection
pressure of prey availability and prey escape. This was particularly evident for the B. atrox Santarém
population, which occupies a floodplain ecological niche, and which annually alternates between
periods of drought and flood [38]. The dry season could accommodate a great taxonomical diversity
of available prey items, but with reduced prey availability, while during the flood non-amphibian
Toxins 2018, 10, 411
14 of 23
prey may be very scarce and amphibians plentiful [38]. In addition to seasonal variability in prey
diversity and availability, there is also a seasonal variation in prey escape potential and a differential
ability to track prey, with amphibian prey items during the flood season having highest degree of
prey escape potential and lowest prey-tracking potential. Thus, the B. atrox Santarém population has
the seasonally highest variation in prey diversity and availability, and highest prey escape potential;
therefore there is a strong evolutionary selection pressure not only for a complex venom active against
a wide diversity of taxon-groups, but also for a fast acting venom capable of rapid prey immobilisation.
This is consistent with the B. atrox (Santarém) venom being the fastest acting and most potent against
all plasma types tested here (Figures 1, 5 and 6). This is consistent with other studies that have
shown that higher prey escape potential selects for faster acting venom [41,65]. Thus while the B. atrox
Santarém population formed slightly weaker clots on the avian plasma than the venoms from the
others populations, it was the fastest acting venom on avian plasma and all other plasmas. This result
suggests that the procoagulant activity in the venom of the Santarém population has an important role
in the subjugation of avian prey, despite the inducement of slightly weaker clots on avian plasma.
Thus, there appears to be a trade-off for speed of action relative to the strength of the clot.
The activation of clotting factors is a de novo activity for the procoagulant enzymes in Bothrops venom.
Neofunctionalisation of serine proteases and metalloproteases for activation of clotting factors, such as
Factor X and prothrombin, are key evolutionary events underpinning the evolutionary success of the
Bothrops genus. This is in comparison to the prothrombin activation by Australian elapid venoms which
have in the venom activated Factor X, which evolved at the base of the Australian snake radiation,
and in the Oxyuranus/Pseudonaja clade, the secondary inclusion of Factor Va [66–68]. Thus in the
Australian elapids there are structural limitations imposed on the venom enzymes due to this historical
contingency, which limits their adaptive flexibility. This is reflective of a fundamental mode of venom
evolution, in which venom glands promiscuously express in the glands proteins which have important
endogenous functions in other tissues [69]. In contrast, since the thrombin generating enzymes in
Bothrops are ancestrally non-clotting enzyme repurposed for a derived clotting function, they have
greater adaptive flexibility.
Therefore, a different sort of selection pressure is operating on repurposed enzymes, such as
in Bothrops, than would be the case for the use of endogenous blood clotting factors as venoms
components such as in Australian elapids. This adaptive flexibility allows for structure-function
evolutions that trade-off of lower efficiency of action for greater speed of action. Thus, the newly
evolved, venom-specific, cleavage site in prothrombin may be different than the cleavage site by the
endogenous prothrombinase complex. For the venom forms, the selection pressure is speed of action,
to produce a stroke inducing blood clot which, therefore, does not have to be as well-ordered or stable
as the blood clot produced during normal blood clotting. In contrast, for endogenous blood clotting,
the selection pressure is for reliable, reproducible formation of stable clots. As the venom enzymes are
repurposed enzymes that have a non-clotting basal function, they are free of the structural constraints
imposed upon the Factor Xa:Factor Va prothrombinase complex, which has been shown to be a limiting
factor for elapid venoms which use Factor Xa as venom component [10]. Consequently, the Bothrops
venom enzymes may have evolved the ability to activate Factor X and prothrombin using cleavage
sites distinct from those of the natural clotting cascade activator.
The unnatural activation of Factor X and prothrombin at cleavage sites upstream or downstream
of the endogenous cleavage site may produce aberrantly active forms of the endogenous clotting
factors FXa or thrombin, which in turn may produce aberrant product when cleaving the next protein in
the clotting cascade, with the cumulative effect of aberrant thrombin cleaving fibrinogen in an aberrant
manner to produce aberrant fibrin clots. For normal blood clotting, such aberrant fibrin clots may have
catastrophic outcomes, but for the snake venoms the effect is neutral as the selection pressure is for
simple induction of stroke. Therefore, an aberrant clot is as effect as a natural clot for the purpose of
prey capture. Thus, the selection pressure is for speed of action, not how well-ordered the fibrin clot is.
Thus, if an aberrant thrombin form cleaves fibrinogen faster than the endogenous form, the selection
Toxins 2018, 10, 411
15 of 23
pressure will be for venom molecules specific for the cleavage site that activate prothrombin into
the fast-acting aberrant form, even if the abberant thrombin in turn produces abberant fibrin clots.
Such clots would still be strong enough to produce a stroke in a prey animal, with such prey subjugation
being the primary evolutionary selection force. Therefore, as the clots are strong enough to satisfy this
selection pressure, speed of clot formation is the function selected for.
It is known that vertebrate blood clotting is more complex in mammals than it is in earlier
diverging vertebrates, involving more haemostasis-related genes than other vertebrates [70,71].
For example, toad plasma lacks the homolog of the human factor XI, and, with the exception of
fibrinogen, all other coagulation factors are found in lower concentrations compared to human
blood [70]. In contrast, toad plasma has a relatively high concentration of antifibrinolytic agents [72].
Birds are deficient in Factor XII, consequently normal avian blood coagulates very slowly in some
testing conditions with clotting times that can exceed 70 min [70,72]. An interesting finding of our
study was that the human thrombin positive control was not able to clot toad plasma (Figure 3).
However, the human FXa was able to clot this plasma, but inducing weaker clots than the venoms.
In this case, the differences found could involve genetic variations underlying the structure of
coagulation factors among the anurans [73,74].
Reflective of these differences was the convergence between speed and clot strength in amphibian
plasma for the B. atrox (Santarém, PA), which predates heavily upon amphibians in the floodplains
that it inhabits. This same prey item has greater escape potential and is the least trackable (in water)
than mammalian prey which are less able to escape and are easier to track (on land), and therefore
there is an extreme selection pressure for speed of action. Thus, the B. atrox (Santarém, PA) venom is
evolving under two novel selection pressures (prey specialization and prey escape), relative to the other
Bothrops venoms in this study. B. atrox (Santarém, PA) is a specialist for a prey item that has a different
clot-inducing landscape than that of avian or mammalian plasmas, therefore exerting a selection
pressure for toxin specialisation. Reflective of the changes in clotting biochemistry with the amphibian
plasma relative to the avian and human plasmas, the thrombin control was inactive against this plasma,
while the Factor Xa control performed poorly. B. atrox (Santarém, PA), however, was substantially faster
at clotting avian and human plasmas than other Bothrops venoms while also producing the strongest
clots in the amphibian plasma and being the fastest on this plasma too. Therefore, this venom displays
the greatest adaptive flexibility of all the venoms in this study. Thus, the two functions (speed of
action versus clot strength), which appear to be mutually exclusive selection pressures in other plasma
for all the Bothrops venoms, appear to be overlapping in the B. atrox (Santarém, PA) venom. This is
indicative of nuances in the amphibian endogenous thrombin in that the form which most quickly
converts fibrinogen to fibrin clots is also the most biochemically efficient in producing strong clots.
In contrast, for the avian and human plasmas the results are indicative of mutually exclusive forms of
thrombin products generated by the venom, in which the thrombin which have the fast rate of action
are not the same forms which produce the best-order, strongest fibrin network. Also noteworthy is
the B. atrox venom from São Bento, which entirely lacked activity on amphibian plasma. This finding
likely reflects a drier habitat and a lower dependence on anurans within the diet, as the São Bento
region is located in a transition zone between the Amazon forest and the Brazilian cerrado—a
different biome. These interesting patterns should be the subject of follow up research examining
the sites of prothrombin which are targeted for cleavage and also the architecture of the fibrin clots
produced by the different thrombin forms. Such variations between different venoms on the same
plasma or the same venom on different plasmas will be a fascinating area of future research.
Together the results in this study contribute to the body of knowledge regarding prey specific
venom effects of coagulotoxins, which have been noted previously for diapsids (bird/reptile) versus
synapsid (mammal) plasmas for B. neuwiedi [49]. Procoagulant variation has been noted between taxon
for other venoms against a range of mammals [75]. However, in other cases taxon-specific procoagulant
effects have not evolved due to constraints imposed by the target site, where mutant forms of
endogenous Factor Xa retains endogenous Factor Xa’s prothrombin cleavage site as a consequence
Toxins 2018, 10, 411
16 of 23
of the historical contingency of this toxin class being formed by venom expressed endogenous
clotting enzymes with structural adaptive limitations [5,69]. Taxon-specific effects have been noted for
neurotoxic actions by colubrid [76–79] and elapid [80–82] venoms. Prey-specific variation in overall
lethality has also been noted for viperid venoms but was not attributed to a specific venom function [83].
In addition, ontogenetic variation in venom composition is also an evolutionary feature, such as the
age-related shift in Pseudonaja species (brown snakes) from neurotoxic venoms in lizard-specialist
neonates, to procoagulant venoms in mammal-specialist adult snakes [67,84].
In summary, this multifaceted study documented variations in coagulotoxic effects and differential
antivenom efficacy within the Bothrops genus, a snake group of extreme medical importance in
South America. Our results revealed new information about the effects of underlying biochemical
variations in venoms, as well as the evolutionary pressures that could be shaping venoms of B. atrox
populations in different locations from the Brazilian Amazon. When tested under physiologically
relevant conditions, the venoms in this study demonstrated procoagulant potencies exceeding that
of other strongly procoagulant genera (tested under identical conditions), such as Echis within the
Viperidae family [8], Notechis within the Elapidae family [5], and Atractaspis within the Lamprophiidae
family [6]. Therefore, the findings here reported bring important insights about issues involving
functional diversity of snake venoms, human envenomations, antivenom efficacy, and also prey-specific
effects, which may be of interest to a broad audience, including clinicians and ecologists.
4. Materials and Methods
4.1. Venoms
B. atrox venom samples were obtained from adult snakes (males and females), captured from nature
(cities of Santarém (in a várzea floodplain habitat) and Belterra (in an upland forest ‘terra firme’ habitat),
State of Pará—under SISBio license 32098-1) and kept in captivity for two years. B. atrox venom
samples, which were obtained from snakes captured at São Bento—State of Maranhão, and Presidente
Figueiredo—State of Amazonas, and kept in captivity for several years, were provided by Laboratório
de Herpetologia and Museu Biológico from Instituto Butantan, respectivally. To account for individual
variation in venom composition, equal amounts of individual venoms were added to prepare four pools
of venoms representing each area, as follows: Santarém n = 9, Belterra n = 10, São Bento n = 10, Presidente
Figueiredo n = 13. The B. jararaca and B. neuwiedi venoms were provided by Herpetarium from Instituto
Butantan (specific collection localities not recorded). The access to the Brazilian genetic heritage was
registered in the SISGEN platform under the number ABEC205. All venom samples were exported under
license from Brazil (export permit: 17BR026238/DF) to Australia (import permit: IP 15016115).
4.2. Antivenom
The polyvalent Bothrops antivenom (batch: 1305077, ED: 05/16), produced by Instituto Butantan,
Brazil, from horses immunised with a pool containing venoms of five Bothrops species:B. jararaca, (50%),
B. neuwiedi (12.5%), B. jararacussu (12.5%), B. alternatus (12.5%), and B. moojeni (12.5%). The antivenom
solution consists of soluble IgG F(ab’)2 fragments and the stipulated potency by manufacturer is:
1 mL neutralises 5 mg of the Bothrops venom of reference. For use in this study’s neutralization
assays, the antivenom was centrifuged (12,000 RCF, 10 min at 4 ◦ C), the supernatant removed, filtered
(0.45 nm filter), aliquoted (1 mL ubes), and stored at 4 ◦ C until use.
4.3. Plasmas
Human plasma was obtained from the Australian Red Cross (Research agreement #18-03QLD-09;
University of Queensland Human Ethics Committee Approval #2016000256). Avian (domestic chicken)
and amphibian (cane toad, Rhinella marina) plasma were obtained under the University of Queensland
Animal Ethics approval SBS/019/14/ARC. All plasma was prepared as 3.2% citrated stock and then
aliquoted into 1 mL quantities, which were snap frozen in liquid nitrogen, and stored at −80 ◦ C
Toxins 2018, 10, 411
17 of 23
until needed, at which time an aliquot was defrosted by placing into a 37 ◦ C water bath for 10 min.
All venom and plasma work was undertaken under University of Queensland Biosafety Approval
#IBC134BSBS2015.
4.4. Coagulation Analyses
Coagulation analyses using a Stago STA-R Max coagulation analysis robot were undertaken as
previously described, with the antivenom diluted to 5% for use in those protocols [5,6,8,9].
4.5. Factor X and Prothrombin Activation Activity
In the activation assays, venom stock solutions at 1 mg/mL (in 50% deionised H2 O: 50% glycerol)
were diluted with OK buffer (Owren Koller Buffer, Stago, Asnières sur Seine, France), 40 µL of
venom into 360 µL of OK buffer. Following, 50 µL of the samples, 50 µL of CaCl2 (25 mM), 50 µL
phospholipid (cephalin prepared from rabbit cerebral tissue from C.K Prest standard kit, Stago,
Asnières sur Seine, France, solubilised in OK buffer) and 25 µL of OK buffer were added automatically
into cuvettes. The mixture was incubated (2 min, 37 ◦ C) before adding 75 µL of a solution containing
the colorimetric substrate (Catalog 00311, Stago, Asnières sur Seine, France) and FX (at 0.01 µg/µL)
or Prothrombin (at 0.1 µg/µL), with a final volume of 250 µL in the cuvette. Changes in the optical
density (OD) were measured each second, for 300 s, using a STA-R Max® automated analyser (Stago,
Asnières sur Seine, France). The activation rates of FX or prothrombin were calculated considering the
OD variation corresponding to cleavage of the substrate by FXa or Thrombin, after the activation of
the zymogens, in relation to direct cleavage of substrate by the venoms in the absence of the zymogen.
Human FXa or thrombin as samples (instead of venom) were used as positive controls to ensure
functionality of the substrate. Each venom, analysed in the same conditions, without the presence of
the zymogens, was used as its own negative control to ensure no direct cleavage of the substrate by
the venom. The results represent the mean ± SD of experiments performed in triplicate.
To investigate the antivenom efficacy against the venom components able to activate FX or
prothrombin, all test conditions from the colorimetric cleavage assays were replicated (Section 4.5),
except that 25 µL of antivenom, from a working solution (50 µL of the reconstituted antivenom in 950 µL
OK buffer), was used in place of 25 µL of OK buffer. Then, reaction mixture was incubated (2 min,
37 ◦ C), before adding 75 µL of the solution containing the colorimetric substrate and FX (at 0.01 µg/µL)
or prothrombin (at 0.1 µg/µL), in a final volume of 250 µL/cuvette, and the cleavage of the substrate
was measured each second for 300 s in the automated analyser (STA-R Max® ). The antivenom efficacy
was calculated comparing the activation rates in the presence vs. the absence of antivenom, and the
results represent the mean ± SD of experiments performed in triplicate.
4.6. Thromboelastography and Fibrinogenolytic Analyses
Were undertaken as previously described [6,85].
4.7. Cleavage of Fibrinogen
Fibrinogen cleavage studies were conducted in 1mm SDS-PAGE gels (12%), as previously
described [85–87].
4.8. Statistical Analyses
All dose-response curves, as well as cofactor dependency tests, were conducted in triplicate
and we present the results as mean and standard deviation. Data were analysed using Prism
7.0 software (GraphPad Software Inc., La Jolla, CA, USA, version 7, 2017, La Jolla, CA, USA).
Tests for correlation were undertaken using the R-studio Pearson correlation function: step 1
tox<-read.csv(file.choose(),header=T); step 2 cor.test(tox$var1,tox$var2).
Toxins 2018, 10, 411
18 of 23
Author Contributions: Conceptualization, L.F.S., A.M.M.d.S. and B.G.F.; methodology: L.F.S., C.N.Z., J.S.D.,
B.o.d.B., F.C.P.C., A.M.M.d.S. and B.G.F.; resources: L.F.S., A.G., A.M.M.d.S., H.d.M.C., S.R.T.C., T.H.M.D.-R.,
M.M.T.-d.-R., K.G., S.S. and B.G.F.; data curation: L.F.S. and B.G.F.; writing: L.F.S., C.N.Z, J.S.D, B.o.d.B., F.C.P.C.,
A.G., A.M.M.d.S. and B.G.F.
Funding: UQ-FAPESP 2017002598 and 2017/50268-0; CAPES-063/2010-Toxinology; and CAPES—Finance
Code 001. LFS is a Ph.D. student of the Sciences Graduate Program—Toxinology (Instituto Butantan) with
the fellowships FAPESP 2014/13124-2 and 2017/15170-0. CNZ, JSD, and BodB were the recipients of University
of Queensland Ph.D. Scholarships.
Conflicts of Interest: The authors declare no conflict of interest.
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
Fry, B.G. Snakebite: When the human touch becomes a bad touch. Toxins 2018, 10, 170. [CrossRef] [PubMed]
Fry, B.G.; Sunagar, K.; Casewell, N.R.; Kochva, E.; Roelants, K.; Scheib, H.; Wüster, W.; Vidal, N.; Young, B.;
Burbrink, F.; et al. The origin and evolution of the Toxicofera reptile venom system. In Venomous
Reptiles and Their Toxins: Evolution, Pathophysiology and Biodiscovery; Fry, B.G., Ed.; Oxford University Press:
New York, NY, USA, 2015; pp. 1–31.
Bos, M.H.A.; van ‘t Veer, C.; Reitsma, P.H. Molecular Biology and Biochemistry of the Coagulation Factors
and Pathways of Hemostasis. In Williams Hematology, 9th ed.; Kaushansky, K., Lichtman, M.A., Prchal, J.T.,
Levi, M.M., Press, O.W., Burns, L.J., Caligiuri, M., Eds.; McGraw-Hill Education: New York, NY, USA, 2016.
Chester, A.; Crawford, G.P. In vitro coagulant properties of venoms from Australian snakes. Toxicon 1982, 20,
501–504. [CrossRef]
Lister, C.; Arbuckle, K.; Jackson, T.N.W.; Debono, J.; Zdenek, C.N.; Dashevsky, D.; Dunstan, N.; Allen, L.;
Hay, C.; Bush, B.; et al. Catch a tiger snake by its tail: Differential toxicity, co-factor dependence and
antivenom efficacy in a procoagulant clade of Australian venomous snakes. Comp. Biochem. Physiol.
Toxicol. Pharmacol. CBP 2017, 202, 39–54. [CrossRef] [PubMed]
Oulion, B.; Dobson, J.S.; Zdenek, C.N.; Arbuckle, K.; Lister, C.; Coimbra, F.C.P.; Op den Brouw, B.; Debono, J.;
Rogalski, A.; Violette, A.; et al. Factor X activating Atractaspis snake venoms and the relative coagulotoxicity
neutralising efficacy of African antivenoms. Toxicol. Lett. 2018, 288, 119–128. [CrossRef] [PubMed]
Pirkle, H.; McIntosh, M.; Theodor, I.; Vernon, S. Activation of prothrombin with taipan snake venom.
Thromb. Res. 1972, 1, 559–568. [CrossRef]
Rogalski, A.; Soerensen, C.; Op den Brouw, B.; Lister, C.; Dashevsky, D.; Arbuckle, K.; Gloria, A.;
Zdenek, C.N.; Casewell, N.R.; Gutierrez, J.M.; et al. Differential procoagulant effects of saw-scaled
viper (Serpentes: Viperidae: Echis) snake venoms on human plasma and the narrow taxonomic ranges of
antivenom efficacies. Toxicol. Lett. 2017, 280, 159–170. [CrossRef] [PubMed]
Debono, J.; Dobson, J.; Casewell, N.R.; Romilio, A.; Li, B.; Kurniawan, N.; Mardon, K.; Weisbecker, V.;
Nouwens, A.; Kwok, H.F.; et al. Coagulating colubrids: Evolutionary, pathophysiological and
biodiscovery implications of venom variations between boomslang (Dispholidus typus) and twig snake
(Thelotornis mossambicanus). Toxins 2017, 9, 171. [CrossRef] [PubMed]
Nielsen, V.G.; Boyer, L.V.; Redford, D.T.; Ford, P. Thrombelastographic characterization of the thrombin-like
activity of Crotalus simus and Bothrops asper venoms. Blood Coagul. Fibrinol. 2017, 28, 211–217. [CrossRef]
[PubMed]
Nielsen, V.G.; Frank, N.; Matika, R.W. Carbon monoxide inhibits hemotoxic activity of Elapidae venoms:
Potential role of heme. BioMetals 2017, 31, 51–59. [CrossRef] [PubMed]
Isbister, G.K.; Woods, D.; Alley, S.; O0 Leary, M.A.; Seldon, M.; Lincz, L.F. Endogenous thrombin potential
as a novel method for the characterization of procoagulant snake venoms and the efficacy of antivenom.
Toxicon 2010, 56, 75–85. [CrossRef] [PubMed]
O0 Leary, M.A.; Isbister, G.K. A turbidimetric assay for the measurement of clotting times of procoagulant
venoms in plasma. J. Pharmacol. Toxicol. Methods 2010, 61, 27–31. [CrossRef] [PubMed]
Still, K.; Nandlal, R.; Slagboom, J.; Somsen, G.; Casewell, N.; Kool, J. Multipurpose HTS coagulation
analysis: Assay development and assessment of coagulopathic snake venoms. Toxins 2017, 9, 382. [CrossRef]
[PubMed]
Toxins 2018, 10, 411
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
19 of 23
Vargas, M.; Segura, A.; Herrera, M.; Villalta, M.; Estrada, R.; Cerdas, M.; Paiva, O.; Matainaho, T.; Jensen, S.D.;
Winkel, K.D.; et al. Preclinical evaluation of caprylic acid-fractionated IgG antivenom for the treatment
of Taipan (Oxyuranus scutellatus) envenoming in Papua New Guinea. PLoS Negl. Trop. Dis. 2011, 5, e1144.
[CrossRef] [PubMed]
Williams, V.; White, J.; Mirtschin, P.J. Comparative study on the procoagulant from the venom of Australian
brown snakes (Elapidae; Pseudonaja spp.). Toxicon 1994, 32, 453–459. [CrossRef]
Resiere, D.; Arias, A.S.; Villalta, M.; Rucavado, A.; Brouste, Y.; Cabie, A.; Neviere, R.; Cesaire, R.; Kallel, H.;
Megarbane, B.; et al. Preclinical evaluation of the neutralizing ability of a monospecific antivenom for
the treatment of envenomings by Bothrops lanceolatus in Martinique. Toxicon 2018, 148, 50–55. [CrossRef]
[PubMed]
Ainsworth, S.; Slagboom, J.; Alomran, N.; Pla, D.; Alhamdi, Y.; King, S.I.; Bolton, F.M.S.; Gutiérrez, J.M.;
Vonk, F.J.; Toh, C.-H.; et al. The paraspecific neutralisation of snake venom induced coagulopathy
by antivenoms. Commun. Biol. 2018, 1, 34. [CrossRef] [PubMed]
Campbell, J.A.; Lamar, W.W. The Venomous Reptiles of the Western Hemisphere; Comstock (Cornell
University Press): Ithaca, NY, USA, 2004; Volume 2.
Warrell, D.A. Snake bites in Central and South America: Epidemiology, clinical features and
clinical management. In The Venomous Reptiles of the Western Hemisphere; Cornell University: Ithaca, NY, USA,
2004; pp. 709–761.
Kasturiratne, A.; Wickremasinghe, A.R.; de Silva, N.; Gunawardena, N.K.; Pathmeswaran, A.; Premaratna, R.;
Savioli, L.; Lalloo, D.G.; de Silva, H.J. The global burden of snakebite: A literature analysis and modelling
based on regional estimates of envenoming and deaths. PLoS Med. 2008, 5, e218. [CrossRef] [PubMed]
França, F.; Málaque, C. Acidente botrópico. In Animais Peçonhentos no Brasil: Biologia, clínica e terapêutica
dos acidentes; 2th ed., Cardoso, J., França, F., Wen, F., Málaque, C., Haddad-Junior, V., Eds.; Sarvier:
São Paulo, SP, Brazil, 2009; pp. 81–95.
Baldo, C.; Jamora, C.; Yamanouye, N.; Zorn, T.M.; Moura-da-Silva, A.M. Mechanisms of vascular damage
by hemorrhagic snake venom metalloproteinases: Tissue distribution and in situ hydrolysis. PLoS Negl.
Trop. Dis. 2010, 4, e727. [CrossRef] [PubMed]
De Queiroz, M.R.; de Sousa, B.B.; da Cunha Pereira, D.F.; Mamede, C.C.N.; Matias, M.S.; de Morais, N.C.G.;
de Oliveira Costa, J.; de Oliveira, F. The role of platelets in hemostasis and the effects of snake venom toxins
on platelet function. Toxicon 2017, 133, 33–47. [CrossRef] [PubMed]
Kini, R.M.; Koh, C.Y. Metalloproteases affecting blood coagulation, fibrinolysis and platelet aggregation from
snake venoms: Definition and nomenclature of interaction sites. Toxins 2016, 8, 284. [CrossRef] [PubMed]
Morita, T. Structures and functions of snake venom CLPs (C-type lectin-like proteins) with anticoagulant-,
procoagulant-, and platelet-modulating activities. Toxicon 2005, 45, 1099–1114. [CrossRef] [PubMed]
Morita, T. Structure-function relationships of C-type lectin-related proteins. Pathophysiol. Haemost. Thromb.
2005, 34, 156–159. [CrossRef] [PubMed]
Serrano, S.M. The long road of research on snake venom serine proteinases. Toxicon 2013, 62, 19–26.
[CrossRef] [PubMed]
Silva, A.; Cristofori-Armstrong, B.; Rash, L.D.; Hodgson, W.C.; Isbister, G.K. Defining the role of post-synaptic
alpha-neurotoxins in paralysis due to snake envenoming in humans. Cell. Mol. Life Sci. 2018. [CrossRef]
[PubMed]
Pardal, P.P.; Souza, S.M.; Monteiro, M.R.; Fan, H.W.; Cardoso, J.L.; Franca, F.O.; Tomy, S.C.; Sano-Martins, I.S.;
de Sousa-e-Silva, M.C.; Colombini, M.; et al. Clinical trial of two antivenoms for the treatment of Bothrops
and Lachesis bites in the north eastern Amazon region of Brazil. Trans. R. Soc. Trop. Med. Hyg. 2004, 98, 28–42.
[CrossRef]
Saldarriaga, M.M.; Otero, R.; Nunez, V.; Toro, M.F.; Diaz, A.; Gutierrez, J.M. Ontogenetic variability of
Bothrops atrox and Bothrops asper snake venoms from Colombia. Toxicon 2003, 42, 405–411. [CrossRef]
Guercio, R.A.; Shevchenko, A.; Shevchenko, A.; Lopez-Lozano, J.L.; Paba, J.; Sousa, M.V.; Ricart, C.A.
Ontogenetic variations in the venom proteome of the Amazonian snake Bothrops atrox. Proteome Sci. 2006,
4, 11. [CrossRef] [PubMed]
Toxins 2018, 10, 411
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
20 of 23
Calvete, J.J.; Sanz, L.; Perez, A.; Borges, A.; Vargas, A.M.; Lomonte, B.; Angulo, Y.; Gutierrez, J.M.;
Chalkidis, H.M.; Mourao, R.H.; et al. Snake population venomics and antivenomics of Bothrops atrox:
Paedomorphism along its transamazonian dispersal and implications of geographic venom variability on
snakebite management. J. Proteom. 2011, 74, 510–527. [CrossRef] [PubMed]
Nunez, V.; Cid, P.; Sanz, L.; De La Torre, P.; Angulo, Y.; Lomonte, B.; Gutierrez, J.M.; Calvete, J.J.
Snake venomics and antivenomics of Bothrops atrox venoms from Colombia and the Amazon regions
of Brazil, Peru and Ecuador suggest the occurrence of geographic variation of venom phenotype by a trend
towards paedomorphism. J. Proteom. 2009, 73, 57–78. [CrossRef] [PubMed]
Salazar, A.M.; Rodriguez-Acosta, A.; Giron, M.E.; Aguilar, I.; Guerrero, B. A comparative analysis of the
clotting and fibrinolytic activities of the snake venom (Bothrops atrox) from different geographical areas
in Venezuela. Thromb. Res. 2007, 120, 95–104. [CrossRef] [PubMed]
Amazonas, D.R.; Portes-Junior, J.A.; Nishiyama, M.Y., Jr.; Nicolau, C.A.; Chalkidis, H.M.; Mourao, R.H.V.;
Grazziotin, F.G.; Rokyta, D.R.; Gibbs, H.L.; Valente, R.H.; et al. Molecular mechanisms underlying
intraspecific variation in snake venom. J. Proteom. 2018, 181, 60–72. [CrossRef] [PubMed]
Gibbs, H.L.; Sovic, M.; Amazonas, D.; Chalkidis, H.; Salazar-Valenzuela, D.; Moura-Da-Silva, A.M.
Recent lineage diversification in a venomous snake through dispersal across the River Amazon. Biol. J.
Linn. Soc. 2018, 123, 1–15. [CrossRef]
Sousa, L.F.; Portes-Junior, J.A.; Nicolau, C.A.; Bernardoni, J.L.; Nishiyama, M.Y., Jr.; Amazonas, D.R.;
Freitas-de-Sousa, L.A.; Mourao, R.H.; Chalkidis, H.M.; Valente, R.H.; et al. Functional proteomic analyses of
Bothrops atrox venom reveals phenotypes associated with habitat variation in the Amazon. J. Proteom. 2017,
159, 32–46. [CrossRef] [PubMed]
Furtado, M.F.; Maruyama, M.; Kamiguti, A.S.; Antonio, L.C. Comparative study of nine Bothrops snake
venoms from adult female snakes and their offspring. Toxicon 1991, 29, 219–226. [CrossRef]
Bénard-Valle, M.; Neri-Castro, E.E.; Fry, B.G.; Boyer, L.; Cochran, C.; Alam, M.; Jackson, T.N.W.; Paniagua, D.;
Olvera-Rodríguez, F.; Koludarov, I.; et al. Antivenom research and development. In Venomous Reptiles
and Their Toxins: Evolution, Pathophysiology and Biodiscovery; Fry, B.G., Ed.; Oxford University Press:
New York, NY, USA, 2015; pp. 61–72.
Sunagar, K.; Undheim, E.A.; Scheib, H.; Gren, E.C.; Cochran, C.; Person, C.E.; Koludarov, I.; Kelln, W.;
Hayes, W.K.; King, G.F.; et al. Intraspecific venom variation in the medically significant Southern Pacific
Rattlesnake (Crotalus oreganus helleri): Biodiscovery, clinical and evolutionary implications. J. Proteom. 2014,
99, 68–83. [CrossRef] [PubMed]
Hofmann, H.; Bon, C. Blood coagulation induced by the venom of Bothrops atrox. 2. Identification, purification,
and properties of two factor X activators. Biochemistry 1987, 26, 780–787. [CrossRef] [PubMed]
Hofmann, H.; Bon, C. Blood coagulation induced by the venom of Bothrops atrox. 1. Identification, purification,
and properties of a prothrombin activator. Biochemistry 1987, 26, 772–780. [CrossRef] [PubMed]
Hofmann, H.; Dumarey, C.; Bon, C. Blood coagulation induced by Bothrops atrox venom: Identification and
properties of a factor X activator. Biochimie 1983, 65, 201–210. [CrossRef]
Santoro, M.L.; Sano-Martins, I.S. Different clotting mechanisms of Bothrops jararaca snake venom on human
and rabbit plasmas. Toxicon 1993, 31, 733–742. [CrossRef]
Maruyama, M.; Kamiguti, A.S.; Tomy, S.C.; Antonio, L.C.; Sugiki, M.; Mihara, H. Prothrombin and factor X
activating properties of Bothrops erythromelas venom. Ann. Trop. Med. Parasitol. 1992, 86, 549–556. [CrossRef]
[PubMed]
Silva, M.B.; Schattner, M.; Ramos, C.R.; Junqueira-de-Azevedo, I.L.; Guarnieri, M.C.; Lazzari, M.A.;
Sampaio, C.A.; Pozner, R.G.; Ventura, J.S.; Ho, P.L.; et al. A prothrombin activator from Bothrops erythromelas
(jararaca-da-seca) snake venom: Characterization and molecular cloning. Biochem. J. 2003, 369, 129–139.
[CrossRef] [PubMed]
Senis, Y.A.; Kim, P.Y.; Fuller, G.L.; Garcia, A.; Prabhakar, S.; Wilkinson, M.C.; Brittan, H.; Zitzmann, N.;
Wait, R.; Warrell, D.A.; et al. Isolation and characterization of cotiaractivase, a novel low molecular weight
prothrombin activator from the venom of Bothrops cotiara. Biochim. Biophys. Acta 2006, 1764, 863–871.
[CrossRef] [PubMed]
Toxins 2018, 10, 411
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
21 of 23
Bernardoni, J.L.; Sousa, L.F.; Wermelinger, L.S.; Lopes, A.S.; Prezoto, B.C.; Serrano, S.M.; Zingali, R.B.;
Moura-da-Silva, A.M. Functional variability of snake venom metalloproteinases: Adaptive advantages in
targeting different prey and implications for human envenomation. PLoS ONE 2014, 9, e109651. [CrossRef]
[PubMed]
Nahas, L.; Kamiguti, A.S.; Barros, M.A. Thrombin-like and factor X-activator components of Bothrops
snake venoms. Thromb. Haemost. 1979, 41, 314–328. [CrossRef] [PubMed]
Sousa, L.F.; Nicolau, C.A.; Peixoto, P.S.; Bernardoni, J.L.; Oliveira, S.S.; Portes-Junior, J.A.; Mourao, R.H.;
Lima-dos-Santos, I.; Sano-Martins, I.S.; Chalkidis, H.M.; et al. Comparison of phylogeny, venom composition
and neutralization by antivenom in diverse species of Bothrops complex. PLoS Negl. Trop. Dis. 2013, 7, e2442.
[CrossRef] [PubMed]
Loria, G.D.; Rucavado, A.; Kamiguti, A.S.; Theakston, R.D.; Fox, J.W.; Alape, A.; Gutierrez, J.M.
Characterization of 0 basparin A,0 a prothrombin-activating metalloproteinase, from the venom of
the snake Bothrops asper that inhibits platelet aggregation and induces defibrination and thrombosis.
Arch. Biochem. Biophys. 2003, 418, 13–24. [CrossRef]
Modesto, J.C.; Junqueira-de-Azevedo, I.L.; Neves-Ferreira, A.G.; Fritzen, M.; Oliva, M.L.; Ho, P.L.; Perales, J.;
Chudzinski-Tavassi, A.M. Insularinase A, a prothrombin activator from Bothrops insularis venom, is
a metalloprotease derived from a gene encoding protease and disintegrin domains. Biol. Chem. 2005,
386, 589–600. [PubMed]
Berger, M.; Pinto, A.F.; Guimaraes, J.A. Purification and functional characterization of bothrojaractivase,
a prothrombin-activating metalloproteinase isolated from Bothrops jararaca snake venom. Toxicon 2008, 51,
488–501. [CrossRef] [PubMed]
Kitano, E.S.; Garcia, T.C.; Menezes, M.C.; Tashima, A.K.; Zelanis, A.; Serrano, S.M. Cotiarinase is a novel
prothrombin activator from the venom of Bothrops cotiara. Biochimie 2013, 95, 1655–1659. [CrossRef] [PubMed]
Niewiarowski, S.; Kirby, E.P.; Brudzynski, T.M.; Stocker, K. Thrombocytin, a serine protease from
Bothrops atrox venom. 2. Interaction with platelets and plasma-clotting factors. Biochemistry 1979, 18,
3570–3577. [CrossRef] [PubMed]
Niewiarowski, S.; Kirby, E.P.; Stocker, K. Throbocytin-a novel platelet activating enzyme from
Bothrops atrox venom. Thromb. Res. 1977, 10, 863–869. [CrossRef]
Kirby, E.P.; Niewiarowski, S.; Stocker, K.; Kettner, C.; Shaw, E.; Brudzynski, T.M. Thrombocytin, a serine
protease from Bothrops atrox venom. 1. Purification and characterization of the enzyme. Biochemistry 1979,
18, 3564–3570. [CrossRef] [PubMed]
Isbister, G.K. Snakebite doesn0 t cause disseminated intravascular coagulation: Coagulopathy and thrombotic
microangiopathy in snake envenoming. Semin. Thromb. Hemost. 2010, 36, 444–451. [CrossRef] [PubMed]
Swenson, S.; Markland, F.S., Jr. Snake venom fibrin(ogen)olytic enzymes. Toxicon 2005, 45, 1021–1039.
[CrossRef] [PubMed]
Markland, F.S. Snake venoms and the hemostatic system. Toxicon 1998, 36, 1749–1800. [CrossRef]
Smith, S.A. The cell-based model of coagulation. J. Vet. Emerg. Crit. Care (San Antonio) 2009, 19, 3–10.
[CrossRef] [PubMed]
Yamada, D.; Sekiya, F.; Morita, T. Prothrombin and factor X activator activities in the venoms of
Viperidae snakes. Toxicon Off. J. Int. Soc. Toxinol. 1997, 35, 1581. [CrossRef]
Daltry, J.C.; Wuster, W.; Thorpe, R.S. Diet and snake venom evolution. Nature 1996, 379, 537–540. [CrossRef]
[PubMed]
Yang, D.C.; Deuis, J.R.; Dashevsky, D.; Dobson, J.; Jackson, T.N.; Brust, A.; Xie, B.; Koludarov, I.; Debono, J.;
Hendrikx, I.; et al. The snake with the scorpion0 s sting: Novel three-Finger toxin sodium channel activators
from the venom of the long-glanded blue coral snake (Calliophis bivirgatus). Toxins 2016, 8, 303. [CrossRef]
[PubMed]
Fry, B.G.; Scheib, H.; van der Weerd, L.; Young, B.; McNaughtan, J.; Ramjan, S.F.; Vidal, N.; Poelmann, R.E.;
Norman, J.A. Evolution of an arsenal: Structural and functional diversification of the venom system in the
advanced snakes (Caenophidia). Mol. Cell. Proteom. 2008, 7, 215–246. [CrossRef] [PubMed]
Jackson, T.N.; Koludarov, I.; Ali, S.A.; Dobson, J.; Zdenek, C.N.; Dashevsky, D.; Op den Brouw, B.; Masci, P.P.;
Nouwens, A.; Josh, P.; et al. Rapid Radiations and the race to redundancy: An investigation of the evolution
of Australian elapid snake venoms. Toxins 2016, 8, 309. [CrossRef] [PubMed]
Toxins 2018, 10, 411
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
22 of 23
Jackson, T.N.; Sunagar, K.; Undheim, E.A.; Koludarov, I.; Chan, A.H.; Sanders, K.; Ali, S.A.; Hendrikx, I.;
Dunstan, N.; Fry, B.G. Venom down under: Dynamic evolution of Australian elapid snake toxins. Toxins
2013, 5, 2621–2655. [CrossRef] [PubMed]
Fry, B.G. From genome to 0 venome0 : Molecular origin and evolution of the snake venom proteome inferred
from phylogenetic analysis of toxin sequences and related body proteins. Genome Res. 2015, 15, 403–420.
[CrossRef] [PubMed]
Doolittle, R.F. Step-by-step evolution of vertebrate blood coagulation. Cold Spring Harb. Symp. Quant. Biol.
2009, 74, 35–40. [CrossRef] [PubMed]
Ribeiro, A.M.; Zepeda-Mendoza, M.L.; Bertelsen, M.F.; Kristensen, A.T.; Jarvis, E.D.; Gilbert, M.T.;
da Fonseca, R.R. A refined model of the genomic basis for phenotypic variation in vertebrate hemostasis.
BMC Evol. Biol. 2015, 15, 124. [CrossRef] [PubMed]
Tentoni, J.; Polini, N.N.; Casanave, E.B. Comparative vertebrate fibrinolysis. Comp. Clin. Pathol. 2010, 19,
225–234. [CrossRef]
Doolittle, R.F.; Feng, D.F. Reconstructing the evolution of vertebrate blood coagulation from a consideration
of the amino acid sequences of clotting proteins. Cold Spring Harb. Symp. Quant. Biol. 1987, 52, 869–874.
[CrossRef] [PubMed]
Ponczek, M.B.; Gailani, D.; Doolittle, R.F. Evolution of the contact phase of vertebrate blood coagulation.
J. Thromb. Haemost. 2008, 6, 1876–1883. [CrossRef] [PubMed]
Maduwage, K.P.; Scorgie, F.E.; Lincz, L.F.; O0 Leary, M.A.; Isbister, G.K. Procoagulant snake venoms have
differential effects in animal plasmas: Implications for antivenom testing in animal models. Thromb. Res.
2016, 137, 174–177. [CrossRef] [PubMed]
Heyborne, W.H.; Mackessy, S.P. Identification and characterization of a taxon-specific three-finger toxin
from the venom of the Green Vinesnake (Oxybelis fulgidus; family Colubridae). Biochimie 2013, 95, 1923–1932.
[CrossRef] [PubMed]
Modahl, C.M.; Mrinalini; Frietze, S.; Mackessy, S.P. Adaptive evolution of distinct prey-specific toxin genes
in rear-fanged snake venom. Proc. Biol. Sci./R. Soc. 2018, 285, 20181003. [CrossRef]
Pawlak, J.; Mackessy, S.P.; Fry, B.G.; Bhatia, M.; Mourier, G.; Fruchart-Gaillard, C.; Servent, D.; Menez, R.;
Stura, E.; Menez, A.; et al. Denmotoxin, a three-finger toxin from the colubrid snake Boiga dendrophila
(Mangrove Catsnake) with bird-specific activity. J. Biol. Chem. 2006, 281, 29030–29041. [CrossRef] [PubMed]
Pawlak, J.; Mackessy, S.P.; Sixberry, N.M.; Stura, E.A.; Le Du, M.H.; Menez, R.; Foo, C.S.; Menez, A.;
Nirthanan, S.; Kini, R.M. Irditoxin, a novel covalently linked heterodimeric three-finger toxin with high
taxon-specific neurotoxicity. FASEB J. 2009, 23, 534–545. [CrossRef] [PubMed]
Hart, A.J.; Isbister, G.K.; Hodgson, W.C. In vitro neurotoxic effects of Pseudechis spp. venoms: A comparison
of avian and murine skeletal muscle preparations. Toxicon 2013, 63, 112–115. [CrossRef] [PubMed]
Hart, A.J.; Isbister, G.K.; O0 Donnell, P.; Williamson, N.A.; Hodgson, W.C. Species differences
in the neuromuscular activity of post-synaptic neurotoxins from two Australian black snakes
(Pseudechis porphyriacus and Pseudechis colletti). Toxicol. Lett. 2013, 219, 262–268. [CrossRef] [PubMed]
Sanhajariya, S.; Duffull, S.B.; Isbister, G.K. Pharmacokinetics of snake venom. Toxins 2018, 10, 73. [CrossRef]
[PubMed]
Gibbs, H.L.; Mackessy, S.P. Functional basis of a molecular adaptation: Prey-specific toxic effects of venom
from Sistrurus rattlesnakes. Toxicon 2009, 53, 672–679. [CrossRef] [PubMed]
Cipriani, V.; Debono, J.; Goldenberg, J.; Jackson, T.N.W.; Arbuckle, K.; Dobson, J.; Koludarov, I.; Li, B.; Hay, C.;
Dunstan, N.; et al. Correlation between ontogenetic dietary shifts and venom variation in Australian brown
snakes (Pseudonaja). Comp. Biochem. Physiol. Toxicol. Pharmacol. CBP 2017, 197, 53–60. [CrossRef] [PubMed]
Coimbra, F.C.P.; Dobson, J.; Zdenek, C.N.; den Brouw, B.O.; Hamilton, B.; Debono, J.; Masci, P.; Frank, N.;
Ge, L.; Kwok, H.F.; et al. Does size matter? Venom proteomic and functional comparison between night adder
species (Viperidae: Causus) with short and long venom glands. Comp. Biochem. Physiol. C Toxicol. Pharmacol.
2018, 211, 7–14. [CrossRef] [PubMed]
Toxins 2018, 10, 411
86.
87.
23 of 23
Dobson, J.; Yang, D.C.; Op den Brouw, B.; Cochran, C.; Huynh, T.; Kurrupu, S.; Sanchez, E.E.; Massey, D.J.;
Baumann, K.; Jackson, T.N.W.; et al. Rattling the border wall: Pathophysiological implications of
functional and proteomic venom variation between Mexican and US subspecies of the desert rattlesnake
Crotalus scutulatus. Comp. Biochem. Physiol. Toxicol. Pharmacol. CBP 2017, 205, 62–69. [CrossRef] [PubMed]
Koludarov, I.; Jackson, T.N.; Brouw, B.O.D.; Dobson, J.; Dashevsky, D.; Arbuckle, K.; Clemente, C.J.;
Stockdale, E.J.; Cochran, C.; Debono, J.; et al. Enter the dragon: The dynamic and multifunctional evolution
of Anguimorpha lizard venoms. Toxins 2017, 9, 242. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).